

AMENDMENT TO THE CLAIMS

The present amendment amends claims 39-42 and adds claim 49. According to 37 C.F.R. § 1.121(c), after entry of the present amendment, the following claims are in the case:

1. (Previously Presented) A kit comprising, in a pharmaceutically acceptable form, biologically effective amounts of at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first antibody, or an antigen-binding fragment thereof, that binds to an aminophospholipid; and at least a second anti-cancer agent other than said at least a first antibody, or an antigen-binding fragment thereof, that binds to an aminophospholipid.
2. (Original) The kit of claim 1, wherein said kit comprises at least a first antibody, or antigen-binding fragment thereof, binds to phosphatidylethanolamine.
3. (Original) The kit of claim 1, wherein said kit comprises at least a first antibody, or antigen-binding fragment thereof, binds to phosphatidylserine.
4. (Original) The kit of claim 1, wherein said kit comprises at least a first IgG or IgM antibody that binds to an aminophospholipid.
5. (Original) The kit of claim 1, wherein said kit comprises at least a first scFv, Fv, Fab', Fab or F(ab')₂ antigen-binding fragment of an antibody that binds to an aminophospholipid.

6. (Original) The kit of claim 1, wherein said kit comprises at least a first monoclonal antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid.
7. (Original) The kit of claim 1, wherein said kit comprises at least a first recombinant antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid.
8. (Original) The kit of claim 1, wherein said kit comprises at least a first human, humanized or part-human chimeric antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid.
9. (Original) The kit of claim 8, wherein said kit comprises at least a first antibody comprising a mouse antibody variable region that binds to an aminophospholipid operatively attached to a human antibody framework or constant region.
10. (Original) The kit of claim 8, wherein said kit comprises at least a first recombinant, human antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid.
11. (Original) The kit of claim 1, wherein said kit comprises at least a first dimer, trimer or multimer of an antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid.

12. (Previously Presented) The kit of claim 1, wherein said kit comprises said first antibody, or an antigen-binding fragment thereof, that binds to an aminophospholipid and a second antibody, or antigen-binding fragments thereof, that binds to an other aminophospholipid.

13. (Original) The kit of claim 12, wherein said kit comprises at least a first antibody, or antigen-binding fragment thereof, that binds to phosphatidylethanolamine and at least a second antibody, or antigen-binding fragment thereof, that binds to phosphatidylserine.

14. (Original) The kit of claim 1, wherein said kit comprises at least a first pharmaceutically acceptable formulation suitable for intravenous administration.

Claims 15-19 canceled

20. (Previously Presented) The kit of claim 1, wherein said at least a first antibody, or antigen-binding fragment thereof, and said at least a second anti-cancer agent are comprised within a single pharmaceutical composition.

21. (Previously Presented) The kit of claim 1, wherein said at least a first antibody, or antigen-binding fragment thereof, and said at least a second anti-cancer agent are comprised within distinct pharmaceutical compositions.

22. (Previously Presented) The kit of claim 1, wherein said at least a second anti-cancer agent is a chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent or apoptosis-inducing agent.

23. (Previously Presented) The kit of claim 1, wherein said at least a second anti-cancer agent is an antibody-therapeutic agent construct comprising a targeting antibody, or antigen-binding fragment thereof, that binds to a surface-expressed, surface-accessible or surface-localized component of a tumor cell, tumor stroma or tumor vasculature; wherein said targeting antibody or fragment thereof is operatively linked to a therapeutic agent.

24. (Original) The kit of claim 23, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a surface-expressed, surface-accessible, surface-localized, cytokine-inducible or coagulant-inducible component of intratumoral blood vessels of a vascularized tumor.

25. (Original) The kit of claim 24, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a surface-expressed component of intratumoral vasculature selected from the group consisting of an aminophospholipid, endoglin, a TGF β receptor, E-selectin, P-selectin, VCAM-1, ICAM-1, PSMA, a VEGF/VPF receptor, an FGF receptor, a TIE, $\alpha_v\beta_3$ integrin, pleiotropin, endosialin and an MHC Class II protein.

26. (Original) The kit of claim 24, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a surface-localized component of intratumoral vasculature selected

from the group consisting of VEGF/VPF, FGF, TGF β , a ligand that binds to a TIE, a tumor-associated fibronectin isoform, scatter factor/hepatocyte growth factor (HGF), platelet factor 4 (PF4), PDGF and TIMP.

27. (Original) The kit of claim 23, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to a cytotoxic agent.

28. (Original) The kit of claim 23, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to a coagulation factor or to an antibody, or antigen-binding fragment thereof, that binds to a coagulation factor.

29. (Original) The kit of claim 23, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to deglycosylated ricin A chain, Tissue Factor, truncated Tissue Factor or to an antibody, or antigen-binding fragment thereof, that binds to Tissue Factor or truncated Tissue Factor.

30. (Previously Presented) The kit of claim 1, wherein said kit further comprises a biologically effective amount of a detectably-labeled antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid.

Claims 31-33 canceled

34. (Previously Presented) A therapeutic kit comprising, in at least a first suitable container, a combined pharmaceutically effective amount of at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first unconjugated antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid; and at least a second anti-cancer agent other than said at least a first unconjugated antibody, or antigen-binding fragment thereof.

35. (Original) The kit of claim 34, wherein said at least a second anti-cancer agent is an anti-angiogenic agent, apoptosis-inducing agent or a vascular targeting agent.

36. (Original) The kit of claim 34, wherein said kit further comprises a diagnostically effective amount of a detectably-labeled antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid.

37. (Original) A medicinal cocktail comprising, in a pharmaceutically acceptable form, a combined effective amount of at least a first anti-cancer agent and at least a first unconjugated antibody, or an antigen-binding fragment thereof, that binds to an aminophospholipid.

38. (Previously Presented) In combination, biologically effective amounts of:

- (a) a detectably-labeled antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid;
- (b) at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first unconjugated antibody, or an antigen-binding fragment thereof, that binds to an aminophospholipid; and

(c) at least a second anti-cancer agent other than said at least a first antibody, or an antigen-binding fragment thereof, that binds to an aminophospholipid.

39. (Currently Amended) A kit comprising at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to kill at least a portion of said tumor vascular endothelial cells upon administration to an animal with a vascularized tumor; said kit further comprising ~~an~~ at least a second anti-cancer agent other than said at least a first antibody that binds to an aminophospholipid.

40. (Currently Amended) A kit comprising at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to induce cell death in at least a portion of said tumor vascular endothelial cells upon administration to an animal with a vascularized tumor; said kit further comprising a therapeutically effective amount of ~~an~~ at least a second anti-cancer agent other than said at least a first antibody that binds to an aminophospholipid.

41. (Currently Amended) A kit comprising at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to effective to occlude or destroy at least a portion of tumor blood vessels upon administration to an animal with a vascularized tumor; said kit further comprising a therapeutically effective amount of ~~an~~ at least a

second anti-cancer agent other than said at least a first antibody that binds to an aminophospholipid.

42. (Currently Amended) A kit comprising at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to induce tumor necrosis, tumor regression or tumor destruction upon administration to an animal with a vascularized tumor; said kit further comprising a therapeutically effective amount of ~~an~~ at least a second anti-cancer agent other than said at least a first antibody that binds to an aminophospholipid.

43. (Previously Presented) The kit of claim 1, wherein said at least a first pharmaceutically acceptable formulation is a liposomal formulation.

44. (Previously Presented) A therapeutic kit comprising, in at least a first suitable container, a combined pharmaceutically effective amount of:

- (a) at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first unconjugated antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of the vascular endothelial cells of the blood vessels of a vascularized tumor; and
- (b) at least a second anti-cancer agent other than said at least a first unconjugated antibody, or antigen-binding fragment thereof, wherein said at least a second anti-cancer agent:

- (i) increases aminophospholipid expression in the endothelium of said blood vessels of said vascularized tumor or injures or induces apoptosis in the endothelium of said blood vessels of said vascularized tumor; or
- (ii) kills tumor cells of said tumor or is an anti-angiogenic agent that inhibits metastasis of tumor cells.

45. (Previously Presented) The kit of claim 44, wherein said at least a second anti-cancer agent increases aminophospholipid expression in the endothelium of said blood vessels of said vascularized tumor or injures or induces apoptosis in the endothelium of said blood vessels of said vascularized tumor.

46. (Previously Presented) The kit of claim 45, wherein said at least a second anti-cancer agent is taxol, vincristine, vinblastine, neomycin, a combretastatin, a podophyllotoxin, TNF- α , angiostatin, endostatin, vasculostatin, an $\alpha_v\beta_3$ antagonist, a calcium-flux inducing agent, a calcium ionophore, H₂O₂, thrombin, an inflammatory cytokine or interleukin-4.

47. (Previously Presented) The kit of claim 44, wherein said at least a second anti-cancer agent kills tumor cells of said tumor or is an anti-angiogenic agent that inhibits metastasis of tumor cells.

48. (Previously Presented) The kit of claim 47, wherein said at least a second anti-cancer agent is an anti-tumor cell immunoconjugate, a chemotherapeutic agent or an anti-angiogenic agent.

49. (New) A kit comprising, in a pharmaceutically acceptable form, biologically effective amounts of at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first antibody, or an antigen-binding fragment thereof, that binds to phosphatidylethanolamine; and at least a second anti-cancer agent other than said at least a first antibody, or an antigen-binding fragment thereof, that binds to phosphatidylethanolamine.